Pfizer enters second AMC-based supply agreement – pneumococcal vaccine

Pfizer said it entered into a second AMC-based supply agreement for its pneumococcal vaccine which “will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease…” Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]) through 2023, “building on its original commitment announced in March 2010 to supply up to 300 million doses of the vaccine under the auspices of the Advance Market Commitment (AMC) for pneumococcal vaccines.” Mark Swindell, president of Vaccines for Pfizer, said, “Pfizer is proud to broaden and extend access to our vaccine to advance public health. Public-private partnership programs like the AMC are vital to accelerating the availability of affordable vaccines, faster than ever before, to those children who are most vulnerable. We are proud to help protect even more children at risk for the potentially devastating consequences of pneumococcal disease – which claims more young children’s lives than any other vaccine-preventable disease.”